The MPN Genomic Calculator uses clinical, laboratory, and genomic characteristics of patients with MPN to estimate their clinical outcomes.
Previously conducted retrospective studies may have underestimated the incidence of hydroxyurea-related skin toxicity in patients with MPNs.
Matched cohort study showed risk greatest for those with primary myelofibrosis, but still high for those with polycythemia vera and essential thrombocythemia.
This study showed that MPN is more aggressive in men vs women and explored whether sex differences in the genomic landscape of MPN could explain this difference.
Anagrelide, a platelet-lowering agent with US FDA approval and EMA licensing for the treatment of patients with ET, is associated with prolonged response to initial therapy.